Our Mission

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) is an international group of rheumatologists and immunologists with special interests in lupus who have been working together on lupus research since 1991. Our mission statement is:

Towards a better world for people with lupus through prevention and improved outcomes

Join us in our mission. We at SLICC, rely completely on the generosity and support of our donors and funders to continue our work.

SLICC developed the Damage Index – the only internationally accepted way of measuring the long-term effects of lupus and its treatment on the body. Without this index, it would be impossible to study those effects over time and compare them between different countries, geographies, and ethnic groups.

SLICC carried out the largest ever study of cancer in patients with lupus – this taught us that only some cancers are more likely to occur in patients with lupus and that the drugs commonly used to treat this disease do not significantly increase this risk of cancer.

But to continue our work, to answer the questions that patients with lupus are asking, we need to invest.

History & Objectives


Since its inception over 25 years ago, SLICC has evolved into a dynamic and expanding research group helping to promote lupus research and collaboration between scientific investigators. Over its history, SLICC has contributed to the development of multiple standardized outcome measures to better characterize lupus activity and damage as well as its response to varying treatments.

Current Activities

SLICC’s Research

SLICC is dedicated to generating new knowledge in the field of lupus, and translating these basic and clinical research discoveries into better health care practices and policies to help provide a healthier future for people diagnosed with lupus.

In 1998, the SLICC group established a longitudinal cohort of newly diagnosed patients with lupus (SLICC Inception Cohort) to better understand risk factors for atherosclerosis and metabolic syndrome, and characterize nervous system involvement.

Our current research activities are focused on atherosclerosis, nervous system involvement, lupus nephritis, and damage accrual, and their economic impact using the inception cohort. New initiatives include development of a pregnancy cohort and working group on microparticles as well as revision of the SLICC/American College of Rheumatology (ACR) Damage Index (SDI).


Organizational Structure

SLICC consists of a Board of Directors and 3 standing committees.

View Governing Body


SLICC is an international research organization with 54 members who, collectively, represent 43 academic medical centres across 16 countries and 5 continents.



Dec 12, 2019

Dr. Rosalind Ramsey-Goldman Receives the ACR Master Designation

Congratulations to Dr. Rosalind Ramsey-Goldman on being a 2019 recipient of the ACR Master Designation. This honor is presented to ACR members how have demonstrated outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession.

Dec 12, 2019

Dr. Michelle Petri Receives ACR Master Designation

Dr. Michelle Petri has recieved the 2019 ACR Master Designation. Recognition as a Master of the American College of Rheumatology is one of the highest honors the College bestows. The honour is awarded to researchers who have made outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession.

Dec 12, 2019

Dr. Susan Manzi receives 2019 Distinguished Clinical Investigator Award

Congratulations to Dr. Susan Manzi on receiving the 2019 American College of Rheumatology, Distinguished Clinical Investigator Award. The Distinguished Clinical Investigator Award is awarded each year to a clinical scientist for making outstanding contributions to the field of rheumatology.